Companies › Bionic Sight
1 active drug program in 2 registered trials: 2 Phase 1; Ophthalmology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BS01 | – | Phase 1 | Retinitis Pigmentosa; Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD) | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04278131 | BS01 | Phase 1 | Retinitis Pigmentosa | Ophthalmology | Dec 2026 |
| NCT07158775 | BS01 | Phase 1 | Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD) | Ophthalmology | Dec 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.